A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

• Status: Recruiting
• Trial end date: 2025-11-01

Summary

This is a Phase 1 study to evaluate the potential drug-drug interaction (DDI) effect of repotrectinib on certain drug transporters in patients with advanced cancer.

• Phase: Phase 1

Details

• Lead Sponsor: Turning Point Therapeutics, Inc.
• Treatments: Calcium; Digoxin; Metformin; Rosuvastatin Calcium